Crossmark

PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

Crossref DOI link: https://doi.org/10.1186/s40425-018-0457-0

Published Online: 2018-12-27

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Carnevalli, Larissa S. https://orcid.org/0000-0001-7432-0195
Sinclair, Charles

Taylor, Molly A.

Gutierrez, Pablo Morentin

Langdon, Sophie

Coenen-Stass, Anna M. L.

Mooney, Lorraine

Hughes, Adina

Jarvis, Laura

Staniszewska, Anna

Crafter, Claire

Sidders, Ben

Hardaker, Elizabeth

Hudson, Kevin

Barry, Simon T.
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

Received: 21 September 2018

Accepted: 20 November 2018

First Online: 27 December 2018

Ethics approval and consent to participate

: Experiments using C57BL/6 J or BALB/cAnNCrl mice were conducted under a U.K. Home Office Project License in accordance with the U.K. Animal (Scientific Procedures) Act 1986 and EU Directive EU 86/609.

: Not applicable.

: All authors are employees of AstraZeneca.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.